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2ABSTRACT
The consortium on dementia with Lewy bodies (CDLB) has established consensus
guidelines for the neuropathologic diagnosis of DLB including the likelihood that the
neuropathologic findings associate with the clinical syndrome. Nevertheless, clinico-pathological
correlations remain controversial. We applied the consensus guidelines for determining Lewy-
related pathology (LRP) and evaluated the clinical presentation in the prospective, population-
based Vantaa 85+ study consisting of individuals at least 85 years of age. LRP was seen in 36% of
304 subjects and categorized as follows: 3% brainstem-predominant, 14% limbic, 15% diffuse
neocortical type (4% could not be categorized). The likelihood that the neuropathology predicts
the DLB clinical syndrome was low in 6%, intermediate in 13% and high in 13% of all 304
subjects. In the latter two groups, 77% were demented, 35% had at least one extrapyramidal
symptom, and 15% had visual hallucinations. Surprisingly, DLB clinical features associated better
with high neurofibrillary stage than with diffuse neocortical LRP. Moreover, the neurofibrillary
stage, substantia nigra (SN) neuron loss and grade of Lewy neurites (LNs) in hippocampal CA2-3
region, each showed a significant association with the extent of LRP. In conclusion, the
neuropathological DLB in this very elderly population was common, but the clinical symptoms
tended to associate better with severe neurofibrillary pathology than with extensive LRP.
Key words: Dementia with Lewy bodies, Lewy-related pathology, ?-synuclein, Alzheimer's
disease, Neurofibrillary pathology, Population-based study, Aging.
3INTRODUCTION:
Dementia with Lewy bodies (DLB), the most frequent ?-synucleinopathy and the second
most common cause of primary neurodegenerative dementia in elderly, is neuropathologically
characterized by the presence of Lewy-related pathology (LRP) i.e. Lewy bodies (LBs) and
dystrophic Lewy neurites (LNs) in the brainstem and cerebral cortex. The consortium on DLB
(CDLB) international workshop proposed consensus guidelines for diagnosis of DLB in 1996 [1],
which were revised in the Third CDLB in 2005 [2]. In addition to advice for categorizing LRP (to
brainstem-predominant, limbic and diffuse neocortical type) based on density and regional
distribution of LBs and LNs detected with ?-synuclein (?S) immunohistochemistry, the Third
CDLB guidelines proposed a probability statement of neuropathologic findings associating with
the DLB clinical syndrome [2]. This statement takes into account the extent of LRP and the often
co-occurring Alzheimer type pathology. The type of LRP can be assigned according to the Third
CDLB guidelines to many cases, but at the same time considerable number of cases remain non-
assignable cases [3, 4]. In addition, the association between the pathology and clinical features has
been variable based on the study designs. Results of case-control studies have seemed to support
the proposed probability statement [2], while studies based on unselected cases have indicated
weaker association between the LRP and clinical features of DLB [4-6]. These discrepant results
have thus challenged the probability statement and the significance of LRP. Besides LRP and
Alzheimer type pathology, the occurrence of clinical features in DLB may depend on other factors
such as neuronal loss. The grade of neuronal loss in the SN has been demonstrated to be one of
the distinguishing factors between Parkinson disease (PD) and pre-symptomatic PD [7, 8].
The aims of this study were to (a) evaluate the frequency of subjects with neuropathologic
DLB, categorized according to the revised consensus guidelines by the Third CDLB [2], (b) to
evaluate how valid the probability statement regarding the clinico-pathologic associations was and




The Vantaa 85+ study cohort includes all 601 residents of Vantaa, a town in Southern
Finland, who were at least 85 years of age on April 1, 1991. The study design has been described
in detail earlier [9, 10]. Results of consented autopsies with neuropathologic examinations and
clinical data were available in 304 (54%) of the 565 eligible study subjects, who died during the
ten-year follow-up by April 1, 2001 (Table 1). This prospective, population-based cohort study
has been approved by the ethics committee of the Health Centre of the city of Vantaa and by the
National Authority for Medicolegal Affairs, Helsinki, Finland.
Clinical assessment
A detailed clinical assessment protocol has been described earlier [10]. Subjects were
considered demented if they fulfilled the guidelines in the Diagnostic and Statistical Manual of
Mental Disorders (third edition, revised; DSM III-R), and the duration of the dementia had been at
least 3 months. In this study, the information regarding the presence of rigidity and hypokinesia
was derived from the last clinical examination prior to death and regarding the occurrence of
visual hallucinations if reported at any time during the follow up. The mean time from the last
clinical examination to death was 16 months (SD 13 months).
Neuropathologic assessment
The brains of the autopsied subjects were fixed in phosphate buffered 4% formaldehyde
for at least 2 weeks before sampling. Tissue samples were obtained following recommendations
5of the First CDLB international workshop [1] for assessing LRP, and for the neuropathologic
staging of neurofibrillary Alzheimer's disease (AD) changes [11]. Thus, the brain samples
included the SN, middle frontal gyrus, superior and middle temporal gyri, inferior parietal lobule,
anterior cingulate gyrus, left and right hippocampus (at the level of the lateral geniculate body),
transentorhinal and entorhinal cortex (at the level of the mamillary bodies), and the primary and
secondary visual cortices (the striate area, parastriate field and peristriate region all represented in
the same specimen).
The Braak stage of neurofibrillary pathology was assessed as described earlier [9].
Sections of SN stained with the haematoxylin and eosin (H&E) method and sections of SN and
right hippocampus stained with antibodies against ?S were used to screen for LRP. In one subject
without a sample of SN, dorsal motor nucleus of vagus and locus coeruleus were used instead. If
any LRP was detected in screened areas, immunohistochemical staining for ?S was performed on
cortical samples obtained from the temporal, frontal, and parietal lobes and cingulate gyrus, as
recommended by the First CDLB [1]. For immunohistochemistry, 98% formic acid (5 minutes)
and microwaving were used for pretreatment, and sections were incubated overnight with the
primary ?S antibody (Transduction Laboratories, Lexington, KY, USA, clone 42, mouse
monoclonal, diluted 1:800). Otherwise immunohistochemistry was done as described earlier in
detail [12].
The load of LRP was semiquantitatively scored (none =0, mild =1, moderate =2, severe
=3 and very severe =4), and followed by the assignment of the type of LRP (none, brainstem-
predominant, limbic, diffuse neocortical) for every subject according to the Third CDLB
guidelines for diagnosis of DLB [2]. Since 45% (50/110) of the subjects with LRP did not
precisely fit to any existing category of LRP, we modified the criteria by allowing score 1 for
parietal lobe within the limbic type of LRP (17 subjects), and score 4 to any area within the
diffuse neocortical type of LRP (8 subjects). Further, 3 subjects with otherwise brainstem-
predominant but with score 1 in one neocortical area were kept in the brainstem-predominant type
6of LRP, and 9 subjects with otherwise limbic but with score 0 in transentorhinal cortex were
included in the limbic type of LRP. Regardless of the modification, 13 subjects with score 1 LRP
confined to the hippocampal-transentorhinal region (without LRP in SN, cingulate gyrus or
neocortex) were not assignable to any of the existing LRP category according to the Third CDLB
guidelines. Thus, these 13 were regarded as a category of their own, which was excluded from the
association analyses. Based on the type of LRP and the Braak stage for neurofibrillary pathology,
the likelihood that observed neuropathology would be associated with the clinical syndrome of
DLB was determined as recommended into low, intermediate and high [2].
Additional investigations included a semiquantitative grading of the cell loss/atrophy in
the ventrolateral tier of SN pars compacta. The grade, extending from none (0) to severe (3), was
determined preferentially by assessing the loss of pigmented neurons, but in borderline cases also
the amount of extraneuronal pigment was considered (Figure 1). The other additional
investigation was the semiquantitative assessment of the LNs in the hippocampal CA 2-3 region
as previously recommended [13].
Statistical methods
Statistical analyses were conducted with SPSS 15.0 program for Windows (SPSS Inc.,
Chicago, IL). For categorical variables the differences between the groups were analyzed with
Chi-Squared or Fisher's exact tests or with Chi-Squared or exact tests for linear trend. Logistic
regression analysis was used to assess association of several predictor variables with dichotomous
dependent variables. p-value ?0.05 was considered significant.
RESULTS
Demographic characteristics (Table 1)
Of the neuropathologically examined subpopulation (n=304), 64 % were demented and
83% were women. The mean age at death was 92.4 years (92.5 years for demented, and 92.1 years
7for non-demented). There were somewhat more demented subjects in the neuropathologically
examined subpopulation compared to the whole study population (64% vs. 58%), but regarding
the other parameters the subpopulation and the whole study population were essentially identical
(Table 1).
Lewy-related pathology
LRP was present in the SN and/or hippocampal-transentorhinal region in 36% (110/304)
of the autopsied subjects (Table 2). Thirteen (4%) subjects had LRP confined to the hippocampal-
transentorhinal region. The remaining 97 LRP positive subjects (32%) - later in the text LRP
refers to these subjects only - were categorized as follows: 8 subjects (3% of 304) were brainstem-
predominant, 42 (14%) were limbic, and 47 (15%) were diffuse neocortical type when the Third
CDLB criteria with our modifications were applied (Table 2). The LRP was somewhat more
common in men (38%) than in women (31%), but the difference was not significant. Most men
with LRP had diffuse neocortical type (65%), while in LRP positive women the frequencies of
limbic (47%) and diffuse neocortical (44%) type were rather equal (Table 2). Neither the category
nor the frequency of LRP was influenced by age in this very elderly population (Table 2).
Braak stage of neurofibrillary pathology and LRP
Among the 304 neuropathologically examined subjects, there were 90 subjects (30%) with
Braak neurofibrillary stage 0, I or II, 142 subjects (47 %) with stage III-IV and 72 subjects (24%)
with stage V-VI. When subjects with LRP and Braak stage 0-II were considered pure DLB
subjects, this group of 26 subjects (27% of LRP positive) included 2 with brainstem-predominant,
12 with limbic, and 12 with diffuse neocortical type of LRP (Table 3).
The Braak stage associated significantly with the extent of LRP (p=0.011, the chi squared
test for linear trend, Figure 2). Anatomically, there was a significant association between the
regional LRP score in transentorhinal cortex and the increasing Braak stage when applying the
8stage in three groups (0-II, III-IV, V-VI, p=0.027), but there was no such association between the
regional LRP score and Braak stage in any other brain area.
When taking both LRP and Alzheimer type neurofibrillary pathology into consideration,
the likelihood that the observed neuropathology was presented with the DLB clinical syndrome
was low in 19 (6 %), intermediate in 39 (13%) and high in 39 (13%) subjects (Table 2). Men had
slightly lower Braak stages compared to women, and at the same time more extensive LRP giving
significantly higher likelihoods for men when comparing men vs. women (p=0.006, Table 2).
Clinical relevance of LRP and neurofibrillary pathology
Dementia. Both the LRP and Braak stage had an effect on the likelihood of dementia
(Table 3). All subjects with diffuse neocortical type and Braak stage V-VI pathology were
demented, but there was also an independent association between dementia and LRP (p=0.021)
and between dementia and Braak stage (p<0.001) when adjusted for gender and age at death.
Among 26 pure DLB subjects (i.e. with LRP and Braak stage 0-II), 50% of both brainstem-
predominant and limbic, and 75% of the diffuse neocortical type subjects were demented.
Subjects with diffuse neocortical disease were 4.3 times (OR, 95% CI 1.7-11.2) more likely to be
demented than subjects without LRP when in the logistic regression analysis adjusted for gender,
age at death, and Braak stage (Table 4). Among the 194 subjects with neurofibrillary pathology
only, 48% of those with Braak stage 0-II, 53% with stage III-IV, and 88% with stage V-VI were
demented (Table 3). The probability for being demented was 8.0 times (OR, 95% CI 3.1-20.9)
higher in subjects with Braak stage V-VI compared to subjects with Braak stage 0-II pathology
when adjusted for gender, age at death and type of LRP (Table 4).
A significant association was also found between dementia and the density of dystrophic
LNs in the hippocampal CA2-3 region (p=0.009, adjusted for gender and age at death). Although
the overall significance of LNs was lost if adjusted for Braak stage, the association of the highest
score of LNs with dementia remained significant (OR 8.8; 95% CI 1.1-71.1; p=0.041).
9 Anatomically, the presence of dementia increased with the increase of regional LRP score
in the transentorhinal cortex independently of the Braak stage (p=0.039, adjusted also for gender
and age at death). In the other brain areas there was no significant association between dementia
and LRP score regardless of the Braak stage.
Extrapyramidal symptoms (EPS) and visual hallucinations. The proportion of subjects
with extrapyramidal symptoms (rigidity and/or hypokinesia) tended to increase along with the
extension of LRP from limbic to the diffuse neocortical type, but also along with the increasing
Braak stage (Tables 3 and 5). Thus, of the subjects with pure diffuse neocortical type of DLB
(Braak stage 0-II), 25% manifested rigidity and hypokinesia, while the corresponding figures of
the subjects with Braak stage V-VI and without LRP were 34% and 24% (Table 5).  The type of
LRP associated significantly with rigidity (p=0.042), as well with hypokinesia (p=0.016), but only
the association with hypokinesia remained significant when adjusted, in addition to gender and
age at death, for Braak stage (p=0.027) and additionally for dementia (p=0.022). However, the
association with hypokinesia was based on the brainstem-predominant type of LRP which
category included only 8 subjects (Table 4). At the same time, Braak stage did not associate with
hypokinesia (p=0.11) but associated with rigidity (p=0.031), though the significance was lost if
adjusted for dementia (p=0.34) or for the type of LRP (p=0.13). It is worth noting, however, that
when both pathologies taken into account, the subjects with diffuse neocortical type and subjects
with Braak stage V-VI both had more or less borderline association with rigidity (p=0.063 and
p=0.075), but only subjects with Braak stage V-VI showed almost significant association with
hypokinesia (p=0.054, Table 4). The LRP score in SN was not associated with rigidity (p=0.17)
nor with hypokinesia (p=0.33).
Visual hallucinations reported in 53 subjects, associated with dementia regardless of the
Braak stage or the type of LRP (OR 4.1; 95% CI 1.7-10.0; p=0.002) and with Braak stage
independently of the presence of dementia (p=0.041), but no association was seen with the type of
LRP (p=0.78). The probability for being presented with visual hallucinations was more than three
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times higher in subjects with Braak stage III-IV or V-VI compared to subjects with Braak stage 0-
II pathology when gender, age at death, type of LRP and dementia all taken into consideration
(Table 4).
Likelihood categories and clinical symptoms. When analyzing the likelihood categories
assessed according to the Third CDLB guidelines [2] and the clinical symptoms, dementia was
most common in the intermediate-likelihood category (85% demented), and least common in the
high-likelihood category (69% demented, Table 3). Rigidity, hypokinesia and visual
hallucinations were most common in the low-likelihood category, within which 47% manifested
rigidity, 37% hypokinesia, and 26% visual hallucinations (Table 5). The subjects with
intermediate and high likelihood of DLB are proposed to be regarded as neuropathologic DLB
[3], within this group of our subjects, 77% were demented, 35% had at least one extrapyramidal
symptom, and 15% had visual hallucinations (Tables 3 and 5).
Findings related to neuronal loss in the SN
Only 7 (2%) of the 303 with SN available did not have any neuron loss in the pars
compacta of SN, 161 (53%) had mild, 115 (38%) had moderate and 20 (7%) had severe neuron
loss. There was a significant positive association between the grade of SN neuron loss and the
LRP score in SN (p<0.001, Figure 3) and the type of LRP (p<0.001). These associations remained
significant even if subjects with the Braak stage V-VI were excluded, most likely because SN
neuron loss did not associate with Braak stage (p=0.37).
The grade of SN neuron loss associated with rigidity (p=0.036), most strongly in the
severe neuron loss group compared to others (OR 3.27; 95% CI 1.30-8.27; p=0.012, adjusted for
gender and age at death). But somewhat unexpectedly no association was seen between the grade




In this study, we evaluated the burden of neuropathologic DLB and related clinical
symptoms in a large prospective, population-based autopsy cohort of very elderly age group,
applying the Third CDLB criteria [2]. The presence of LRP in the brains of these subjects at least
85 years of age was common: even 20% of non-demented showed neuropathologic DLB
classifiable to brainstem-predominant, limbic or diffuse neocortical type, while the corresponding
figure for those with dementia was 38% and in the whole neuropathologically examined
subpopulation 32%. Furthermore, it is of interest that a great majority (92%) of the LRP positive
subjects had a more extensive, i.e. limbic or diffuse neocortical type of distribution. However, in
present study neuropathologic DLB did not really predict the clinical symptoms commonly
related with DLB: one fifth of the subjects with limbic or diffuse neocortical type were not
demented and almost two thirds of them did not have a single EPS. Based on the likelihood
categories [2], 26% of our subjects had extensive ?-synucleinopathy corresponding to the
intermediate and high likelihood, but neither did these predict the DLB clinical syndrome: almost
one fourth were not demented and two thirds did not have a single EPS.
Comparisons with previous studies
The frequency of LRP in all screened areas in our study was 36%, which is almost
identical to the previously reported prevalence (37%) in an elderly population (MRC CFAS study)
from UK [14]. Our results are also consistent with those of a recently published population-based
Hisayama study in which 31% of demented elderly Japanese individuals had LRP; among these
23% had limbic or diffuse neocortical type, and altogether 16% showed an intermediate or high
likelihood that neuropathology was related to the clinical DLB syndrome [3]. The lower
frequencies reported in the Hisayama study [3] may well be explained by the younger mean age of
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the subjects in that study (mean age at death for demented subjects in Hisayama study was 86.2
years vs. 92.5 years in our study).
DLB is reported to affect men with slight excess [15]. Our results are consistent with that
impression, but it is important that our subpopulation included only 17% men. Nevertheless, this
study suggests that neuropathologic DLB is slightly more frequent in men also among individuals
aged 85 years and older, and men most often exhibit diffuse neocortical type of LRP. On the other
hand, the presence of LRP in men seemed to be less often associated with the clinical symptoms
than in women. Earlier studies have concluded that the frequency of LRP increases and LRP
extends wider with age [3, 16], even between the eighth and tenth decades [17]. In our study, we
could not find the evidence - within this limited age range of very elderly subjects - for age being
a risk factor for LRP. It may be that the frequency of LRP increases along with aging only until a
certain age.
Neuropathologic evaluation of the proposed categorization of LRP
The neuropathologic diagnosis of DLB was based on the Third CDLB recommendation
[2]. According to this, the types of LRP were defined as none, brainstem predominant, limbic and
diffuse neocortical. Due to the overlapping scores in present staging scheme [2], and because the
LRP score could vary significantly from one anatomic region to another, the determination of a
“correct” type was problematic in almost half of the subjects. Actually, according to the revised
criteria, some individuals could have been included in any of the proposed three types, depending
on the interpretation. Some samples were particularly problematic - for example, according to the
proposed guidelines, score 1 for LRP in the parietal lobe is allowed only for the diffuse
neocortical type [2], in which it is expected that other neocortical areas were also affected.
However, our subpopulation contained several individuals who showed score 1 LRP in the
parietal lobe without any LRP in the other neocortical samples. On the other hand, 8 subjects had
score 4 in the neocortex based on the suggested scoring scheme for LRP, compared to the
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expected "maximum" score of 3 in the Third CDLB criteria [2]. In addition, according to our
results, it seems possible that there are also subjects who show focal LRP in the cerebrum without
such pathology in the brainstem. The current categorization of LRP types does not acknowledge
that possibility.
Other researchers have also had difficulties in defining the type LRP according the current
guidelines, and modified criteria have been proposed [3, 18]. Further, Leverenz and colleagues
suggest in their modified protocol to investigate only the frontal sample of the neocortical areas
[18], which our findings argue against because we did not find any association between dementia
and LRP score in the samples of frontal cortex. In contrast, the burden of LRP in the
transentorhinal cortex associated with the increasing Braak stage, and also strongly with dementia
regardless of the Braak stage, indicating that this sample may be useful when clinico-pathological
association regarding dementia are evaluated in DLB patients.
Clinico-pathological association
The likelihood categories [2] in unselected autopsy studies have shown moderate accuracy
for dementia and EPS [4]. It appears that the clinical DLB syndrome has a positive association to
the extent of LRP and a negative association to the severity of Alzheimer type pathology [2, 6],
i.e. subjects with pure DLB present more often with DLB core symptoms compared to those with
severe concomitant Alzheimer type pathology. Especially those with extensive neurofibrillary
pathology have been reported to show fewer clinical features of DLB, like visual hallucinations
[19, 20]. Our findings did differ from those results since visual hallucinations did associate
significantly with the Braak stage but not with LRP. Interestingly, hypokinesia seemed to be
associated with brainstem-predominant type of LRP and, more or less significantly, with Braak
stage V-VI but not at all with diffuse neocortical DLB.
In our study rigidity was significantly associated with the neuron loss in SN but not with
the LRP burden in SN. However, the most severe neuron loss of SN was seen in subjects with
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diffuse neocortical type of LRP who also had severe LRP burden in SN. There was no association
between rigidity and the type of LRP if also Braak stage taken into account. In our study there
was a borderline association between EPS and Braak stage V-VI as well between EPS and diffuse
neocortical DLB, though these were lost if adjusted for dementia. Therefore, the competing
effects of DLB and AD may well explain, why the association between the EPS and LRP in our
study and in another population-based study [3] did not convincingly correlate with the likelihood
categories [2]. Our results suggest that it might be helpful to take into account the neuron loss of
SN while assessing whether the clinically detected rigidity was related with the LRP or Alzheimer
type pathology (Braak stage).
The process of LRP formation has been suggested to be triggered by AD pathology [21].
Jellinger and colleagues have found correlation between the Braak Parkinson stage and Braak
neurofibrillary AD stage [22, 23]. The detected association between the extent of LRP and the
Braak stage of neurofibrillary pathology in our study is in line with those results. These findings
suggest interaction between ?S and tau, as has been suggested also based on the genetic studies
[24]. Thus, hypothetically the end-stage of DLB would be diffuse neocortical distribution of LRP
with severe neurofibrillary pathology. In this case, exclusion of subjects with frequent Alzheimer
type pathology would misguide us in association analyses. Yet, the Third CDLB criteria of
likelihood categories [2] are emphasized to find “pure” DLB behind the clinical features. Thus, in
our very elderly subjects, high likelihood category did not predict the DLB clinical syndrome.
Strengths and weaknesses of this study
To the best of our knowledge, this is one of the first population-based studies focusing on
LRP in very elderly age groups. The study population included all individuals of 85 years of age
and older who lived in one town at one time-point, and thus there was no selection bias in the
original cohort. The clinical follow-up examinations were done by a neurologist who used the
same protocol throughout the study. The use of clinical and social care notes improved the
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accuracy of the diagnosis of dementia [25]. Autopsy frequency was over 50% during the ten-year
follow-up – a figure, which is one of the highest among population-based autopsy studies [26].
As shown in Table 1, there were hardly any differences between the autopsied subpopulation and
all deceased during the follow-up period. The 6 percent-units difference in the frequency of
subjects with dementia between the autopsied subpopulation and the whole study population has
only a minor effect on the estimated frequency of LRP in the whole study population. We
calculated the dementia-adjusted frequency of LRP by weighting the frequency of classifiable
LRP among the demented (38%) and non-demented (20%) subjects in the autopsied
subpopulation with the proportion of the demented (0.58) and non-demented (0.42) subjects in the
whole study population. The result was 30% which is only 2 percent-units less than the proportion
found among the autopsied subpopulation.
The clinical syndrome of DLB was not commonly known when the clinical study started
in April 1991. This explains why the clinical examination protocol did not include assessing of
the REM sleep behaviour, neuroleptic sensitivity, functional neuroimaging, and why no attention
was paid to recognition of fluctuation in cognition [2]. For evaluating the parkinsonism and
psychiatric symptoms we did not use the UPDRS or in the 1994 published NPI evaluation system,
but the evaluation was done systematically based on the clinical standard of that time. Errors in
the assessment of clinical features, such as delusions considered visual hallucinations, or
inaccurate assessment of hypokinesia and rigidity are, of course, possible when assessing subjects
in this oldest old age group, most of who represent with dementia and are confined to bed. This
may have effect on our poor association between the DLB likelihood categories and clinical
symptoms.
Since, all subjects of the neuropathologically examined subpopulation had died by April
2001, the sampling protocol followed the recommendations of the First CDLB in which a sample
of amygdala was not included [27]. Thus, our sampling protocol did not follow exactly the more
recent guidelines [2]. As both guidelines indicate that SN is always affected in DLB [1, 2], we
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used SN to screen for LRP in our neuropathologically examined subjects. Due to our interest in
the frequency of LRP in the hippocampal CA 2-3, the other sample used for screening was
hippocampus with the posterior edge of the transentorhinal cortex. Because we did not use
amygdala or dorsal motor nucleus of vagus for additional screening, nor did examine the cortical
samples of every subject, we may have missed some LRP positive brain areas. Nevertheless, it is
unlikely that we have missed any or at least a significant number of cases of limbic or neocortical
DLB. For example in the Hisayama study [3], only two of the 71 subjects with LRP had limbic or
cortical pathology without LRP in SN or transentorhinal cortex. Furthermore, the other of these
two subjects had score 1 in the parietal lobe (see also above!) only and was included in the no-
LRP group. The other had score 3 in the amygdala without any LRP in the cortical samples. The
amygdala may show marked LRP without that pathology in any other brain area, especially when
associated with AD [28]. The clinical impact of LRP in amygdala is still largely unknown [29],
but a category of their own has been proposed to these “amygdala only” subjects [6, 18]. We
found 13 not classifiable cases with LRP restricted to the hippocampal-transentorhinal region.
Further studies are needed to investigate, whether these are associated and combinable with the
"amygdala only" subjects.
Conclusions
The Third CDLB guidelines [2] propose a method to define the likelihood that observed
neuropathology accounts for DLB clinical syndrome. However, in very elderly people even
extensive LRP is not necessarily accompanied by recognizable clinical symptoms, and the
"correct" clinical symptoms are not necessarily associated with LRP. Thus, although the clinical
diagnosis of DLB may be reliable if the disorder occurs in relatively pure form, the diagnosis is
likely to be challenging in the very elderly people, who may have multiple pathologies in their
brains. Further studies are needed to investigate how to distinguish clinically the effects of LRP
from those of other pathologies, what is the pathogenic relationship between LRP and Alzheimer
17
type pathology, and whether the age of subjects affects the threshold of appearance of the various
clinical features of DLB.
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Men 118 (21%)   52 (17%)
Women 447 (79%) 252 (83%)
Dementia status (n, %)
Demented 326 (58%) 196 (64%)
Non-demented 239 (42%) 108 (36%)
Frequency of dementia (n, %)
Men   63 (53%)   30 (58%)
Women 263 (59%) 166 (66%)
Age at onset (mean ± SD) 86.8 (±4.5) 87.1 (±4.5)
Duration of dementia (mean ± SD)   5.2 (±3.5)   5.4 (±3.7)
Age at death (mean ± SD) 91.9 (±3.6) 92.4 (±3.7)
Age at death (n, %)
85-89 188 (33%)   82 (27%)
90-94 267 (47%) 146 (48%)
>95 110 (19%)   76 (25%)
Hospitalization at death
Hospital 431 (76%)** 238 (78%)
Nursing home   99 (18%)   55 (18%)
Home   26 (5%)   11 (4%)
* The study population includes all subjects who deceased during the ten-year follow-up time and
had approved to participate in the study
** For nine the hospitalization at the death not known
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Table 2 Distribution of Lewy-related pathology (LRP) and likelihood categories according to the age at death and gender.
Type of LRP Likelihood category
Age at death _None ±Non- +Brainstem- +Limbic +Diffuse Low Intermediate High
classifiable predominant Neocortical likelihood likelihood likelihood
All
Total n=304 194 (64%) 13 (4%) 8 (3%) 42 (14%) 47 (15%) 19 (6%) 39 (13%) 39 (13%)
Men n=52 30 (58%) 2 (4%) 1 (2%) 6 (12%) 13 (25%) 1 (2%) 5 (10%) 14 (27%)*
Women n=252 164 (65%) 11 (4%) 7 (3%) 36 (14%) 34 (13%) 18 (7%) 34 (13%) 25 (10%)*
85-89 years
Total n=82 50 (61%) 3 (4%) 1 (1%) 12 (15%) 16 (20%) 4 (5%) 14 (17%) 11 (13%)
Men n=15 10 (67%) 0 (0%) 0 (0%) 2 (13%) 3 (20%) 0 (0%)   1 (7%)   4 (27%)
Women n=67 40 (60%) 3 (5%) 1 (1%) 10 (15%) 13 (19%) 4 (6%) 13 (19%)   7 (10%)
90-94 years
Total n=146 95 (65%) 7 (5%) 4 (3%) 22 (15%) 18 (12%) 10 (7%) 17 (12%) 17 (12%)
Men n=23 13 (57%) 1 (4%) 1 (4%) 3 (13%) 5 (22%) 1 (4%) 4 (17%)   4 (17%)
Women n=123 82 (67%) 6 (5%) 3 (2%) 19 (15%) 13 (11%) 9 (7%) 13 (11%) 13 (11%)
?95 years
Total n=76 49 (65%) 3 (4%) 3 (4%) 8 (11%) 13 (17%) 5 (7%) 8 (11%) 11 (14%)
Men n=14 7 (50%) 1 (7%) 0 (%) 1 (7%) 5 (36%) 0 (0%) 0 (0%)   6 (43%)
Women n=62 42 (68%) 2 (3%) 3 (5%) 7 (11%) 8 (13%) 5 (8%) 8 (13%)   5 (8%)
_LRP negative subjects
± LRP confined to the hippocampal-transentorhinal region only
+ Regarded as LRP subjects in the text and analyses
*A significant difference in the presence of likelihood categories between men and women (p=0.006)
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Table 3 Likelihood categories according to the type of Lewy-related pathology (LRP) and Alzheimer type neurofibrillary pathology (Braak stage), with
frequency of dementia and at least one extrapyramidal symptom (EPS) i.e. rigidity and/or hypokinesia.
Alzheimer type neurofibrillary pathology
Type of LRP Braak stage 0-II Braak stage III-IV Braak stage V-VI
None
n=194 n=60 n=101 n=33
112 demented (58%) 29 demented (48%) 54 demented (53%) 29 demented (88%)
54 with EPS (28%) 12 with EPS (20%) 27 with EPS (27%) 15 with EPS (45%)
Brainstem-predominant Low likelihood Low likelihood Low likelihood
n= 8 n=2 n=3 n=3
5 demented (63%) 1 demented (50%) 2 demented (67%) 2 demented (67%)
5 with EPS (63%) 1 with EPS (50%) 2 with EPS (67%) 2 with EPS (67%)
Limbic High likelihood Intermediate likelihood Low likelihood
n=42 n=12 n=19 n=11
29 demented (69%) 6 demented (50%) 13 demented (68%) 10 demented (91%)
12 with EPS (29%) 2 with EPS (17%) 5 with EPS (26%) 5 with EPS (45%)
Diffuse neocortical High likelihood High likelihood Intermediate likelihood
n=47 n=12 n=15 n=20
41 demented (87%) 9 demented (75%) 12 demented (80%) 20 demented (100%)
20 with EPS (43%) 5 with EPS (42%) 7 with EPS (47%) 8 with EPS (40%)
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Table 4 Associations of Lewy-related pathology and Alzheimer type neurofibrillary pathology
with clinical features based on logistic regression analysis.
Model I* Model II**
OR 95% CI p-value OR 95% CI p-value
Rigidity
No LRP 1 1
Brainstem 3.48  0.81-14.99 0.094 3.86  0.82-18.09 0.087
Limbic 1.34 0.61-2.96 0.467 1.22 0.54-2.72 0.629
Diffuse Neocortical 2.03 0.96-4.27 0.063 1.59 0.74-3.38 0.233
Braak stage 0-II 1 1
Braak stage III-IV 1.09 0.54-2.18 0.815 1.03 0.50-2.10 0.945
Braak stage V-VI 2.00 0.93-4.31 0.075 1.45  0.66-3.20 0.357
Hypokinesia
No LRP 1 1
Brainstem 7.82 1.73-35.34 0.008 9.51 1.94-46.70 0.006
Limbic 0.63 0.23-1.74 0.372 0.56 0.20-1.58 0.274
Diffuse Neocortical 1.47 0.67-3.23 0.343 1.15 0.52-2.57 0.729
Braak stage 0-II 1 1
Braak stage III-IV 1.67 0.76-3.66 0.201 1.59 0.71-3.56 0.257
Braak stage V-VI 2.35 0.99-5.60 0.054 1.64 0.68-4.01 0.271
Visual hallucinations
No LRP 1 1
Brainstem 1.23 0.22-6.79 0.813 1.27 0.22-7.43 0.793
Limbic 0.72 0.27-1.90 0.507 0.63 0.24-1.68 0.353
Diffuse Neocortical 1.02 0.43-2.42 0.963 0.81 0.34-1.92 0.625
Braak stage 0-II 1 1
Braak stage III-IV 3.22 1.26-8.20 0.014 3.23 1.25-8.37 0.016
Braak stage V-VI 4.49 1.63-12.36 0.004 3.29 1.17-9.21 0.023
Dementia
No LRP 1
Brainstem 0.82 0.17-3.99 0.806
Limbic 1.50 0.71-3.19 0.292
Diffuse Neocortical 4.32 1.66-11.24 0.003
Braak stage 0-II 1
Braak stage III-IV 1.27 0.72-2.24 0.400
Braak stage V-VI 8.02 3.08-20.91 <0.001
OR; Odds Ratio, 95% CI; 95% Confidence Interval
* The ORs are adjusted for gender and age at death, and mutually for type of LRP and Braak
stage.
 ** The ORs are adjusted for gender, age at death, and dementia, and mutually for type of
LRP and Braak stage.
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Table 5 The presence of the clinical features according to the type of LRP and Alzheimer type neurofibrillary pathology (Braak stage).
Type of LRP Braak stage 0-II Braak stage III-IV Braak stage V-VI
None, n=194 60 (31%) 101 (52%) 33 (17%)
Rigidity 11 (18%)   16 (16%) 11 (33%)
Hypokinesia   6 (10%)   18 (18%)   9 (27%)
Visual hallucinations   5 (8%)   19 (19%) 10 (30%)
Brainstem-predominant, n=8   2 (25%)+     3 (38%)+   3 (38%)+
Rigidity   1 (50%)     2 (67%)   1 (33%)
Hypokinesia   1 (50%)     2 (67%)   2 (67%)
Visual hallucinations   0 (0%)     1 (33%)   1 (33%)
Limbic, n=42 12 (29%)*   19 (45%)** 11 (26%)+
Rigidity   1 (8%)     5 (26%)   5 (45%)
Hypokinesia   1 (8%)     2 (11%)   2 (18%)
Visual hallucinations   0 (0%)     3 (16%)   3 (27%)
Diffuse Neocortical, n=47 12 (26%)*   15 (32%)* 20 (43%)**
Rigidity   3 (25%)     6 (40%)   7 (35%)
Hypokinesia   3 (25%)     4 (27%)   5 (25%)
Visual hallucinations   1 (8%)     5 (33%)   3 (15%)
+ Low likelihood category
** Intermediate likelihood category
* High Likelihood category
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FIGURE LEGENDS
Figure 1 Assessment of the neuron loss in the substantia nigra (SN). Hematoxylin and eosin
(H&E) staining (x200) illustrating the severing loss of pigmented neurons in SN.
Figure 2 Alzheimer type neurofibrillary pathology (Braak stage) according to the distribution of
classifiable Lewy-related pathology (p=0.011, the chi squared test for linear trend).
Figure 3 The neuron loss of the substantia nigra (SN) according to (A) Lewy-related pathology
(LRP) score in SN (p<0.001, the SPSS linear-by-linear exact test), and (B) the distribution of LRP
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